Preclinical Stage Market Partnering Terms and Agreements 2010-2015 is a latest researched report available at ReportsnReports.com. The Preclinical Stage Market Partnering Terms and Agreements 2010-2015 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
Preclinical Stage Market Partnering Terms and Agreements 2010-2015 report provides a detailed understanding and analysis of how and why companies enter preclinical stage market partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all preclinical stage market partnering deals announced since 2010 including financial terms where available including over 2,000 links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Purchase Report @ http://www.reportsnreports.com/Purchase.aspx?name=242994
Single User License USD 2995
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
Chapter 5 provides a review of trends in preclinical stage deal making since 2010. Deals are listed by big pharma and big biotech dealmaking in preclinical stage, deal type, therapy type and technology type.
Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.
Inquire for more information @ http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=242994
Chapter 7 provides a review of the leading preclinical stage deal by headline value.
Chapter 8 provides a comprehensive listing of the top 50 big pharma and top 50 big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2010 organized by stage of development – preclinical.
Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=242994
The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2010.
In addition, a comprehensive appendix is provided organized by partnering company A-Z , deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Preclinical Stage Partnering Terms and Agreements 2010-2015 provides the reader with the following key benefits:
- In-depth understanding of preclinical stage deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,000 preclinical stage deals together with contract documents if available
- Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Identify leading preclinical stage deals by value since 2010
- Identify the most active preclinical stage dealmakers since 2010
- Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.